Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CDP870

Known as: CDP870s, 870s, CDP, 870, CDP 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2010
Review
2010
  • Y. Wu, B. Zhou
  • British Journal of Cancer
  • 2010
  • Corpus ID: 14944496
Tumour necrosis factor-alpha (TNF-α) is an important inflammatory factor that acts as a master switch in establishing an… Expand
  • figure 1
  • figure 2
Highly Cited
2007
Highly Cited
2007
Background: Inhibitors of tumor necrosis factor &agr; (TNF&agr;) have demonstrated significant efficacy in chronic inflammatory… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 7
Review
2007
Review
2007
A variety of targets for therapeutic intervention are based upon advances in understanding of the immunopathogenesis of Crohn’s… Expand
Highly Cited
2005
Highly Cited
2005
BACKGROUND & AIMS To investigate the efficacy and safety of certolizumab pegol (a polyethylene-glycolated Fab' fragment of anti… Expand
Highly Cited
2004
Highly Cited
2004
Absorption Prediction.- Predicting Molecular Physical Properties.- In Silico Transporter Modeling and Its Application in Drug… Expand
  • table 1.1
  • figure 1.1
  • figure 1.2
  • figure 1.3
  • figure 2.1
Highly Cited
2004
Highly Cited
2004
Background : CDP870 is a PEGylated Fab′ fragment of a humanized monoclonal antibody that neutralizes tumour necrosis factor‐α. 
Review
2003
Review
2003
  • W. Sandborn
  • Current gastroenterology reports
  • 2003
  • Corpus ID: 21127649
The introduction of infliximab, a mouse/human chimeric monoclonal antibody to tumor necrosis factor (TNF), is an important… Expand
Highly Cited
2002
Highly Cited
2002
OBJECTIVE Biological products that neutralize tumour necrosis factor alpha (TNF-alpha) are beneficial in rheumatoid arthritis (RA… Expand